Zhi Tong Cai Jing·2026-01-09 14:38Core Viewpoint - Novo Nordisk's stock price increased by over 3.6% to $59.41 following Amazon Pharmacy's announcement to offer Wegovy oral tablets, the first FDA-approved oral GLP-1 medication for weight management [1] Group 1: Product Availability - Amazon Pharmacy has begun providing Wegovy oral tablets, making it more accessible to eligible commercial insurance users with a minimum monthly out-of-pocket cost of $25 [1] - For uninsured consumers, a transparent self-pay option is available starting at $149 per month [1] Group 2: Consumer Support and Delivery - The platform allows users to compare insurance payment prices with self-pay prices, automatically applying eligible coupons at checkout to help consumers choose the best payment method [1] - Wegovy oral tablets can be quickly delivered to customers across all 50 states in the U.S., with same-day delivery available for nearly half of American users [1] Group 3: Market Implications - This move broadens Wegovy's accessibility and highlights Amazon's strategic focus on expanding its presence in the healthcare and prescription drug distribution sectors [1] - The increasing demand for GLP-1 weight loss medications, combined with the entry of e-commerce and digital health platforms, may have a profound impact on traditional pharmacies and drug distribution channels [1]